Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

WALGREENS BOOTS ALLIANCE, INC.

(WBA)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
41.66 USD   -0.24%
11/23WALGREENS BOOTS ALLIANCE, INC. Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K/A)
AQ
11/22S&P closes at more than two-month high on retail, energy lift
RE
11/22Retailer, energy boost helps Wall Street rally
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

CVS, Walmart reach $147.5 mln opioid settlement with West Virginia

09/20/2022 | 03:51pm EST

Sept 20 (Reuters) - CVS Health Corp and Walmart Inc have agreed to pay $147.5 million to settle West Virginia's claims over their alleged roles in the state's opioid crisis, state attorney general Patrick Morrisey said Tuesday.

CVS agreed to pay $82.5 million and Walmart agreed to pay approximately $65 million, according to the state.

West Virginia had been prepared to proceed to trial on Sept. 26 against the two companies, as well as Walgreens Boots Alliance.

The state had accused the pharmacy chains of fueling the deadly opioid epidemic through their allegedly lax oversight of prescription pills sold in the state.

Walgreens has not settled, and a trial has been rescheduled for June 2023.

"We believe that we have a very strong case against Walgreens," Morrisey said at a news conference. "We're going to pursue that quite vigorously."

Kroger Co. will also be a defendant in the rescheduled June 2023 trial.

West Virginia has been particularly hard hit by the epidemic, with a per capita opioid mortality rate over three times the national average in 2020, according to data from the National Center for Health Statistics.

CVS said that it will continue to defend itself in other opioid lawsuits, but believed that "putting these claims behind us" was the right decision in the West Virginia case.

"Our position remains that opioid prescriptions are written by doctors, not pharmacists, and that opioid medications are made and marketed by manufacturers, not pharmacies," CVS spokesman Michael DeAngelis said.

Walmart and Walgreens did not immediately respond to a request for comment.

More than 3,300 lawsuits have been filed against drugmakers, distributors and pharmacies over the crisis.

The litigation has increasingly targeted pharmacy chains in recent months, after drug makers and distributors reached major nationwide settlements, including a $26 billion deal with the three leading drug distributors and Johnson & Johnson, addressing their liabilities.

Walgreens has resisted settlements in other opioid cases brought by state and local governments this year. It was the last defendant to settle a lawsuit over Florida's opioid claims, and it was the sole defendant to go to trial over San Francisco's opioid claims.

Walgreens was found liable for fueling opioid addiction in San Francisco, and the amount it must pay will be determined in a future trial.

Walgreens, CVS and Walmart were found liable for contributing to the opioid crisis in two Ohio counties, and were ordered to pay $650 million in that case. (Reporting by Dietrich Knauth; editing by Bill Berkrot, Alexia Garamfalvi and Richard Pullin)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
CVS HEALTH CORPORATION 1.20% 101.26 Delayed Quote.-1.84%
KROGER CO. (THE) 2.51% 49.04 Delayed Quote.8.35%
WALGREENS BOOTS ALLIANCE, INC. -0.24% 41.66 Delayed Quote.-20.13%
WALMART INC. 0.43% 153.07 Delayed Quote.5.79%
All news about WALGREENS BOOTS ALLIANCE, INC.
11/23WALGREENS BOOTS ALLIANCE, INC. Change in Directors or Principal Officers, Financial St..
AQ
11/22S&P closes at more than two-month high on retail, energy lift
RE
11/22Retailer, energy boost helps Wall Street rally
RE
11/22Wall St climbs on retail, energy lift
RE
11/22Wall St gains as Best Buy calms fears of dull holiday season
RE
11/22Factbox-Pharmacies, drug companies settle lawsuits over U.S. opioid crisis
RE
11/22Wall Street rises on gains in Walgreens, Best Buy
RE
11/22Wall St set to open higher on gains in Walgreens, Best Buy
RE
11/22Cowen Upgrades Walgreens Boots Alliance to Outperform From Market Perform, Adjusts Pric..
MT
11/22Futures flat after slipping on China lockdown worries
RE
More news
Analyst Recommendations on WALGREENS BOOTS ALLIANCE, INC.
More recommendations
Financials (USD)
Sales 2023 133 B - -
Net income 2023 3 224 M - -
Net Debt 2023 8 242 M - -
P/E ratio 2023 11,7x
Yield 2023 4,70%
Capitalization 36 028 M 36 028 M -
EV / Sales 2023 0,33x
EV / Sales 2024 0,31x
Nbr of Employees 262 500
Free-Float 60,9%
Chart WALGREENS BOOTS ALLIANCE, INC.
Duration : Period :
Walgreens Boots Alliance, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WALGREENS BOOTS ALLIANCE, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 41,66 $
Average target price 41,70 $
Spread / Average Target 0,10%
EPS Revisions
Managers and Directors
Rosalind Gates Brewer Chief Executive Officer & Director
James Kehoe Global Chief Financial Officer & Executive VP
Stefano Pessina Executive Chairman
Kevin M. Ban Global Chief Medical Officer & Executive VP
Hsiao Wang Chief Information Officer & Senior Vice President